flecainide has been researched along with Cardiac Conduction Defect in 4 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Previous reports on the long-term use of sodium channel blockers in LQT3 are sparse." | 5.48 | Long-term flecainide therapy in type 3 long QT syndrome. ( Benhorin, J; Chorin, E; Flint, N; Medina, A; Taub, R; Viskin, S, 2018) |
| " Previous reports on the long-term use of sodium channel blockers in LQT3 are sparse." | 1.48 | Long-term flecainide therapy in type 3 long QT syndrome. ( Benhorin, J; Chorin, E; Flint, N; Medina, A; Taub, R; Viskin, S, 2018) |
| "However, the mechanisms of cardiac arrhythmias in DM1 are unknown." | 1.42 | Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1. ( Algalarrondo, V; Azibi, K; Balse, E; Beldjord, C; Coulombe, A; Duboc, D; Eymard, B; Fischmeister, R; Gourdon, G; Hatem, SN; Sebag, F; Wahbi, K, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimizu, T | 1 |
| Kawai, S | 1 |
| Kawada, A | 1 |
| Wakamiya, T | 1 |
| Nakano, Y | 1 |
| Watanabe, S | 1 |
| Iwamoto, M | 1 |
| Chorin, E | 1 |
| Taub, R | 1 |
| Medina, A | 1 |
| Flint, N | 1 |
| Viskin, S | 1 |
| Benhorin, J | 1 |
| Algalarrondo, V | 1 |
| Wahbi, K | 1 |
| Sebag, F | 1 |
| Gourdon, G | 1 |
| Beldjord, C | 1 |
| Azibi, K | 1 |
| Balse, E | 1 |
| Coulombe, A | 1 |
| Fischmeister, R | 1 |
| Eymard, B | 1 |
| Duboc, D | 1 |
| Hatem, SN | 1 |
| Carrasco, JI | 1 |
| Izquierdo, I | 1 |
| Medina, P | 1 |
| Arnau, MÁ | 1 |
| Salvador, A | 1 |
| Zorio, E | 1 |
4 other studies available for flecainide and Cardiac Conduction Defect
| Article | Year |
|---|---|
Combined mexiletine and flecainide for severe long QT syndrome type 3.
Topics: Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Electrocardiography; Flecainide; Humans; | 2023 |
Long-term flecainide therapy in type 3 long QT syndrome.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Cardiac Conduction System Disease; Chil | 2018 |
Abnormal sodium current properties contribute to cardiac electrical and contractile dysfunction in a mouse model of myotonic dystrophy type 1.
Topics: Action Potentials; Aging; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; C | 2015 |
Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
Topics: Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Electrocardiography; Female; Flecainide; | 2012 |